Results 121 to 130 of about 75,992 (272)

Radiotherapy and Immunotherapy In Hepatocellular Carcinoma: Priming the Tumor Immune Microenvironment From Bench To Bedside

Precision Radiation Oncology, EarlyView.
The dual immunomodulatory network of radiotherapy in hepatocellular carcinoma. Radiotherapy initiates its effects by inducing immunogenic cell death and DNA double‐strand breaks. Immune Activation: Cytosolic DNA from damaged cells activates the cGAS‐STING pathway, triggering IRF3/NF‐κB‐mediated type I interferon production. This enhances dendritic cell
Zhigang Fu, Yang Zhang, Zuomin Wang, Zongjuan Li, Shisuo Du   +4 more
wiley   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation

Respirology, EarlyView.
The association between baseline neutrophil‐to‐lymphocyte ratio (NLR) and severe checkpoint inhibitor pneumonitis (CIP) was analyzed in discovery retrospective and validation prospective cohorts. Higher baseline NLR (≥ 4.75) was associated with increased severe CIP incidence in both cohorts.
Tetsu Hirakawa, Kakuhiro Yamaguchi, Shun Takao, Nobuhiro Kanaji, Naoko Matsumoto, Kozue Miyazaki, Tamio Okimoto, Chihiro Ando, Hisao Higo, Masaaki Yanai, Koji Kurose, Yasunari Nagasaki, Masako Watanabe, Kosuke Oyama, Yuko Toyoda, Yoshihiro Taguchi, Shimpei Tada, Kiyofumi Shimoji, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada, Noboru Hattori   +24 more
wiley   +1 more source

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison

Frontiers in Oncology
BackgroundThe effectiveness of immune checkpoint inhibitors (ICIs) as adjuvant therapy for muscle-invasive urothelial carcinoma (MIUC) with high recurrence risk has been demonstrated.
Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii   +8 more
doaj   +1 more source

Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy.

, 2018
A 71-year-old caucasian man developed a new onset cholestasis of unknown origin. His past medical history includes non-small cell lung cancer with cerebral metastasis treated by surgery, chemotherapy and nivolumab immunotherapy.
M Komuta, F Clinckart, N Lanthier, de Vos, Marie, Lanthier, Nicolas, Nicaise, Gregory, M de Vos, Hamoir, Coralie, Clinckart, Frédéric, C Hamoir, G Nicaise, Komuta, Mina   +11 more
core   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source

Painful Bilateral Necrosis of the Scalp

JEADV Clinical Practice, EarlyView.
Zoé Dumesnil, Manuel Croix, Anael Dumont, Kottler Diane, Mohamed‐Taha Tagmouti, Anne Dompmartin, Jean‐Matthieu L'Orphelin   +6 more
wiley   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Nivolumab — perspectives in cancer treatment

, 2016
Blockade of the immune checkpoint PD-1 is a new and promising strategy for the treatment of advanced cancers. The introduction of nivolumab has improved prognosis in a large group of cancer patients.
Rutkowski, Piotr, Koseła, Hanna; Department of Soft Tissue, Bone Sarcoma and Melanoma, Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland   +1 more
core  

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam, M Figura, J Heyer, S Lieber, M Huber, KL Loveland, HC Schuppe, Daniela Fietz   +7 more
wiley   +1 more source